VOGX (Vogenx) Research & Development: $ Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VOGX Vogenx Inc VOGX
8 GF Score
Price $14.09
View Full Analysis

What is Vogenx Research & Development?

Vogenx VOGX +8.38% 8 Research & Development is $ Mil as of Dec. 2025. GuruFocus rates VOGX with a GF Score™ of 8/100.

Research & Development is the aggregate amount of research and development expenses during the year. Vogenx's Research & Development for the six months ended in Dec. 2025 was $0.57 Mil. Vogenx does not have enough years/quarters to calculate the Research & Development for the trailing twelve months (TTM) ended in Dec. 2025.

Vogenx  (NAS:VOGX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Vogenx Research & Development Related Terms

Vogenx Research & Development Historical Data

* Premium members only.

The historical data trend for Vogenx's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vogenx Research & Development Chart

Vogenx Annual Data
Trend Dec24 Dec25
Research & Development
1.32 0.57

Vogenx Semi-Annual Data
Dec24 Dec25
Research & Development 1.32 0.57
VOGX
8GF Score
Vogenx Inc VOGX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vogenx Research & Development Calculation

This is the expense the company spent on research and development.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $ Mil mean?
Vogenx (VOGX) has a Research & Development of $ Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Vogenx and its competitors.
Is Vogenx's Research & Development too high?
Vogenx's current Research & Development is $ Mil. Overall, Vogenx has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Vogenx's Research & Development compare to ?
Vogenx's Research & Development of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Vogenx and its competitors. Vogenx's current Research & Development is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vogenx stock overvalued right now?
Vogenx (VOGX) has a current Research & Development of $ Mil. The current Research & Development is $ Mil. Vogenx's overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Vogenx (VOGX), the current Research & Development is $ Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vogenx Business Description

Comparable Companies
Address 3901 Barrett Drive, P.O. Box 19469, Suite 300, Raleigh, NC, USA, 27609
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.
8GF Score

Get the complete analysis for VOGX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.09
Price